Society sets a limit of what it is prepared to pay and then developers must decide whether its worth developing drugs for small indications at that pricepoint.
The ags and the refiners had a spirited move to start the third quarter and continued well: CF Industries (NYSE:CF), Monsanto (NYSE:MON), Agrium (NYSE:AGU), Mosaic (NYSE:MOS), the ones we focus on for the Pricepoint Sheet and Off the Charts.